Loading clinical trials...

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT00604214

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with ...

Lead sponsor: Eli Lilly and Company•23 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 4

Aminoglycosides in Early Sepsis

NCT06712641 · Sepsis

RECRUITING

ACOD1 as a Prognostic Marker for Sepsis

NCT07533994 · Sepsis

RECRUITINGNA

Peripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients

NCT07367113 · Sepsis, Septic Shock, and more

RECRUITING

Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on Echovirus 11

NCT07356583 · Enterovirus, Clinical Syndrome, and more

RECRUITING

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810 · Acute Kidney Injury, Acute Kidney Injury Due to Sepsis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 18, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment1,696

Start dateMar 2008

Last updatedSep 18, 2012

Condition

Sepsis

Locations shown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Birmingham, Alabama

Loma Linda, California

Long Beach, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 18, 2012Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Aminoglycosides in Early Sepsis

ACOD1 as a Prognostic Marker for Sepsis

Peripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients

Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on Echovirus 11

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Trial snapshot

Condition

Locations shown

For caregivers